ResearcherMirna Therapeutics, Inc.No recent work listed
Aiming Yu
Matched on ORCID iD 0000-0003-1441-4012; OpenAlex author ID A5079729783; NIH RePORTER profile ID 8294076. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 2)
- Trials
- 0
- Grants
- 2
- Labs led
- 1
- Collaborators
- 7
2014: 1 grant · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 grant · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper
Papers 4
- A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer. Co-author DOI 10.1007/s00280-022-04457-9↗
- Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. Last author DOI 10.1016/j.canlet.2018.10.038↗
- Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.tranon.2019.01.009↗
- MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Last author DOI 10.18632/oncotarget.9999↗
Grants 2
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Edward Jae-Hoon Kim · 4 shared papers, 2016–2022 · strength 0.40
- Paper A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumo… DOI 10.1007/s00280-022-04457-9↗
- Paper Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. DOI 10.1016/j.tranon.2019.01.009↗
- Paper Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. DOI 10.1016/j.canlet.2018.10.038↗
- Mei‐Juan Tu · 3 shared papers, 2016–2019 · strength 0.27
- Paper Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. DOI 10.1016/j.tranon.2019.01.009↗
- Paper Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. DOI 10.1016/j.canlet.2018.10.038↗
- Paper MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. DOI 10.18632/oncotarget.9999↗
- Andreas G Bader · 1 shared grant, 2014 · strength 0.18
- Justin A. Chen · 1 shared paper, 2022 · strength 0.13
- Thomas John Semrad · 1 shared paper, 2022 · strength 0.13
- Zhijian Duan · 1 shared paper, 2019 · strength 0.10
- Richard J. Bold · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.